What’s New and What’s Next in the Treatment of MDS?

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Release Date: March 29, 2019
Expiration Date: March 29, 2020

Expected time to complete this activity as designed: 60 minutes

There are no fees for participating in or receiving credit for this online activity.

Program Overview

MediCom Worldwide, Inc. is pleased to have collaborated with the MDS Foundation on the development of this activity. Myelodysplastic syndromes are a group of small-incidence malignancies that represent a significant challenge to many community oncologists. In this activity, participants will hear from two key experts about a variety of topics including, but not limited to: personalized risk stratification, iron overload, immunotherapies, and new strategies for treating lower- and higher-risk MDS. Join Dr. Sekeres and Dr. Steensma as they discuss incorporating molecular abnormalities into diagnosis and prognosis, and where luspatercept and imetelstat may fit into the future of MDS treatment.

Target Audience

This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, nurses, pharmacists and other allied healthcare professionals who provide care to patients with myelodysplastic syndromes.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Outline expert faculty perspectives on new updates to diagnostic guidelines in MDS, including the emerging role of molecular genetic profiles in disease identification and prognostication
  • Describe expert faculty perspectives on key clinical trial data for novel therapies, treatment strategies and emerging therapeutic options for the management of anemia in MDS
  • Recognize the potential impact of ongoing trials on clinical practice and existing treatment paradigms in MDS

Agenda

What’s New and What’s Next in the Treatment of MDS? – Mikkael A. Sekeres, MD, MS, and David P. Steensma, MD, FACP

Instructions for Participation and Credit

This activity is eligible for credit through March 29, 2020. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME and CNE may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biography

Mikkael A. Sekeres, MD, MS
Professor of Medicine
Director, Leukemia Program
Vice Chair for Clinical Research
Cleveland Clinic
Cleveland, Ohio

Dr. Mikkael Sekeres earned a medical degree and a master’s degree in clinical epidemiology from the University of Pennsylvania School of Medicine. He completed his postgraduate training at Harvard University, finishing an internal medicine residency at Massachusetts General Hospital, and a fellowship in hematology-oncology at the Dana-Farber Cancer Institute in Boston. Dr. Sekeres is Professor of Medicine, Director of the Leukemia Program, and Vice Chair for Clinical Research at the Cleveland Clinic Taussig Cancer Institute. In addition, he is Deputy Associate Director for Clinical Research of the Case Comprehensive Cancer Center in Ohio.

Dr. Sekeres chaired the Oncologic Drugs Advisory Committee of the FDA and is co-chair of the medical advisory board of the Aplastic Anemia and Myelodysplastic Syndromes (MDS) International Foundation. He is a member of the American Society of Hematology, the American Society of Clinical Oncology, and the Southwest Oncology Group—Leukemia Committee. Dr. Sekeres is an invited speaker at numerous meetings, grand rounds, and conferences. He is the author/co-author of hundreds of abstracts published in Blood, Journal of Clinical Oncology, Nature Genetics, Journal of the National Cancer Institute, PLoS One, Cancer, Haematologica, and Leukemia. He is also the co-author of six books, editor-in-chief of the ASH Clinical News magazine, is on the editorial board of several journals, and is an essayist for The New York Times and Huffington Post. Dr. Sekeres’ current research focuses on patients with MDS and older adults with acute myeloid leukemia, and he has been the national primary study investigator on several phase I/II trials.

David P. Steensma, MD, FACP
Associate Professor of Medicine
Harvard Medical School
Institute Physician
Dana-Farber Cancer Institute
Boston, Massachusetts

Dr. David Steensma received his medical degree from the University of Chicago’s Pritzker School of Medicine. He completed an internal medicine residency and a combined hematology-oncology fellowship at the Mayo Clinic in Rochester, Minnesota. He is Associate Professor of Medicine at Harvard Medical School and Institute Physician in the Division of Hematological Malignancies at Dana-Farber Cancer Institute in Boston, Massachusetts, where he co-directs the hematological malignancy precursor clinic. In addition, Dr. Steensma is a consulting physician at Brigham & Women’s Hospital.

Following completion of his formal training, Dr. Steensma spent several years as a visiting research scholar in the Molecular Haematology Unit of the Weatherall Institute of Molecular Medicine, University of Oxford, England, investigating the molecular genetics of myelodysplastic syndromes. He is board certified by the American Board of Internal Medicine in internal medicine, hematology, and medical oncology. Dr. Steensma has published more than 300 peer-reviewed papers, served as editor for several American Society of Hematology (ASH) publications, education co-chair for the ASH Annual Meeting, section editor for the Journal of Clinical Oncology, member of the FDA Oncology Drug Advisory Committee, and on the hematology examination committee of the American Board of Internal Medicine.

Accreditation

MediCom CME CREDIT
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ACPE CPE CREDIT
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit.
Universal Activity Number: 827-0000-19-010-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.

MediCom NURSING CREDIT
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 19-010-100

Disclosure

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosure

Dr. Mikkael Sekeres has received honoraria related to formal advisory activities from Celgene Corporation, Syros Pharmaceuticals, Inc., and Takeda Oncology.

Dr. David Steensma has received honoraria as a consultant from Novartis AG, Otsuka Pharmaceutical Co., Ltd., and Sensei Biotherapeutics as well as formal advisory activities from Onconova Therapeutics, PharmaEssentia Corporation, and Takeda Oncology.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Kristin Burke and Andrea Mathis, Project Managers, and Joan Meyer, RN, MHA, Executive Director, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at lisa@medicaled.com.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Astex Pharmaceuticals and Celgene Corporation

©2019 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.